- Question from SPW: What's the news on neratinib?
- Answers - Eric Winer, M.D. Neratinib is an agent like lapatinib, but it may be more effective. That said, it also probably has more side effects. There are ongoing trials with neratinib looking at it in women receiving their initial treatment for metastatic breast cancer and for women in the adjuvant setting. Neratinib is what's called a small molecule, and it gets into the HER2-positive cancer cells and prevents HER2 from stimulating the growth of the cancer cell.
The Ask-the-Expert Online Conference called Updates From the 2010 San Antonio Breast Cancer Symposium featured Eric Winer, M.D. and Marisa Weiss, M.D. answering your questions about the latest updates on breast cancer risk, screening, and treatment in early and metastatic breast cancer.
Editor's Note: This conference took place in December 2010.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.